Trial Profile

A Phase 1, Randomized, Double Blind, Dose-escalation, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-2004 in Healthy Subjects

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 25 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SHR-2004 (Primary)
Indications Arterial thrombosis; Venous thrombosis
Focus Adverse reactions
Sponsors Beijing Suncadia Pharmaceuticals

Most Recent Events

12 Dec 2023 Results assessing the safety, tolerability, PK / PD and immunogenicity of SHR-2004 in healthy chinese subjects, presented at the 65th American Society of Hematology Annual Meeting and Exposition
29 Nov 2022 Status changed from recruiting to active, no longer recruiting.
06 Jun 2022 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com